Bioinformatics Scientist, CNS Transcriptomics (Alnylam Pharmaceuticals, Cambridge MA, USA) Apply Here: https://www.linkedin.com/jobs/view/1654082305/

Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipel\ine of investigational RNAi therapeutic medicines, including five programs in late-stage development. Alnylam currently has two commercial RNAi therapeutic products. The first product is approved in the U.S., EU, Canada, Japan, and Switzerland for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults and the second product is approved in the U.S. for the treatment of adults with acute hepatic porphyria (AHP). Alnylam also has a deep pipeline of investigational medicines, including five product candidates that are in late-stage development. Headquartered in Cambridge, Mass., Alnylam employs over 1,300 people in 18 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe’s Top Places to Work five years in a row (2015-2019), a Great Place to Work in the U.K. and Switzerland in 2019 and Science Magazine’s #1 Top Employer in 2019. Please visit www.alnylam.com for more information.

We seek a talented and experienced Bioinformatics Scientist to analyze internal and external transcriptomic data with a focus on the central nervous system (CNS). Building on our success of two FDA approvals in the past 16 months, and with definitive pre-clinical evidence of gene knockdown in mammalian brains, Alnylam is expanding its portfolio of RNAi therapeutic target tissues to CNS, as well as the eye. These ambitious scientific, clinical and commercial goals demand a deep understanding of the transcriptomic landscape of complex tissues. We seek an experienced bioinformatician with domain knowledge in relevant fields (e.g. NGS, scRNA-Seq, neuroscience) who will work in an interdisciplinary team of data scientists, biologists, and chemists to enhance our understanding of CNS transcriptomics. We offer the chance to actively participate in the rational, sequenced-based design and development of an RNAi therapeutic on a team with demonstrated success in bringing novel drug modalities to patients. We also have a great and innovative culture. Take the word of our peers. Alnylam was named the number one biopharma employer by Science Magazine in 2019.

Summary of Key Responsibilities

• Use and develop cutting-edge analysis and visualization methods to understand cell-type efficacy and target specificity signatures from CNS RNA-Seq data
• Leverage external gene expression datasets to understand molecular signatures of human disease physiology in the CNS
• Use RNA-Seq data to help derive RNAi therapeutic pharmacodynamic models in CNS cell types
• Professionally maintain code in a version-controlled repository
• Present results of computational analyses to interdisciplinary teams of scientists
• Provide scientific leadership within the Alnylam community in CNS transcriptomics
• Work to improve the lives of patients

Qualifications

• We prefer a PhD in a CNS disease relevant field, but will actively consider all with substantial professional experience
• Significant (>2 years) experience in NGS analysis required
• scRNA-Seq experience preferred but not required
• Mastery of programming and scripting languages (we are a Python/R/C++ shop) and significant experience working in Unix is essential
• Experience with cloud-based computing e.g. AWS a plus
• The ability to confidently present clear, concise data analyses to a multidisciplinary audience is essential